The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.
By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying ...
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...
Find the latest pfizer vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the ...
The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements for vaccine approvals in lower-risk groups, a policy championed by FDA ...
LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results